MIT family translocation renal cell carcinoma

Summary

MIT family translocation renal cell carcinoma (MONDO:0017886) is a cancer and 5 clinical trials. Top therapeutic interventions include ipilimumab and sasanlimab. A subtype of renal cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	MIT family translocation renal cell carcinoma
Mondo ID	MONDO:0017886
Orphanet	319308
DOID	DOID:0081413
NCIT	C154494
SNOMED CT	764694005
UMLS	C4518356
MedGen	1376834
GARD	0017446
Is cancer (heuristic)	yes

Also known as: carcinoma associated with MITF/TFE translocation · translocation renal cell carcinoma

Data availability: 7 cell lines.

Disease family

This is a subtype of renal cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › renal cell carcinoma › MIT family translocation renal cell carcinoma

Related subtypes (10): mucinous tubular and spindle renal cell carcinoma, renal pelvis adenocarcinoma, Wolffian duct adenocarcinoma, collecting duct carcinoma, renal cell adenocarcinoma, cystic renal cell carcinoma, kidney medullary carcinoma, adrenal cortex carcinoma, nonpapillary renal cell carcinoma, acquired cystic disease-associated renal cell carcinoma

Subtypes (3): renal cell carcinoma, Xp11-associated, TFEB-rearranged renal cell carcinoma, childhood renal cell carcinoma with MiT translocations

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04413123	PHASE2	ACTIVE_NOT_RECRUITING	Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT06835972	PHASE1/PHASE2	RECRUITING	A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07123090	PHASE2	RECRUITING	A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
NCT06318871	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IPILIMUMAB	4	1
SASANLIMAB	3	1